Co-founder and CEO, Mirxes
For detecting disease (almost) before it starts
To Lihan Zhou, early detection is the best medicine. The co-founder of rapidly growing biotechnology company Mirxes, he helped to develop the use of MicroRNA (MiRNA) to locate nascent cancers, and develop the Fortitude Covid-19 detection system, producing a million tests weekly. In 2021, Mirxes raised US$87 million in Series C funding and established Southeast Asia’s largest Industry 4.0 in vitro diagnostic (IVD) manufacturing facility.